Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL By Ogkologos - August 6, 2026 9 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BRUIN CLL-322 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC MOST POPULAR Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... August 31, 2022 FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma August 22, 2025 Teclistamab Results in a High Rate of Deep and Durable Response... August 22, 2022 FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma March 30, 2021 Load more HOT NEWS This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... Commemorating and Making History: The National Cancer Act 50th Anniversary
